Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Elicera Therapeutics.

    Client Virtual Booth

    ELICERA THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Elicera Therapeutics
    Sweden Flag
    Country
    Country
    Sweden
    Address
    Address
    World Trade Center Göteborg Mässans gata 10, floor 7 412 51, Göteborg
    Telephone
    Telephone
    +46 (0)70-331 90 51‬
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.elicera.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics

    Details:

    Under the terms of the agreement, Elicera will grant a world-wide non-exclusive license to Immunicum for the purpose of using the viral vector to label immune cells or tumor cells with exogenous antigens for therapeutic purposes.


    Lead Product(s): Ad5PTD

    Therapeutic Area: Oncology Product Name: Ad5PTD

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Immunicum AB

    Deal Size: $0.5 million Upfront Cash: $0.2 million

    Deal Type: Licensing Agreement January 05, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Elicera Therapeutics Files a Patent Application for the Development of the Next Generation Oncolytic Viruses

    Details:

    ELC-201 is based on an adenovirus that has been genetically engineered to make the treatment suitable to a wide range of cancer, and the patent application further protects the application of two more genetic alterations, giving the drug candidate three modes of action.


    Lead Product(s): ELC-201

    Therapeutic Area: Oncology Product Name: ELC-201

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 27, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search